A T Shaw1, J Yan2, S A Kuhstoss3, J F Charles2,4, E M Gravallese4. 1. Department of Medicine, Division of Rheumatology, University of Massachusetts Chan Medical School, Worcester, MA, USA. 2. Department of Orthopedic Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. 3. Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA. 4. Department of Medicine, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Abstract
OBJECTIVE: The Wnt signalling antagonist Dickkopf-1 (DKK1) inhibits osteoblast differentiation and function and has been described to play a central role in promoting bone loss, while blockade of DKK1 increases bone formation. We investigated the effects of DKK1 on periosteal new bone formation in two murine models of inflammatory arthritis, the antigen-induced arthritis (AIA) and K/BxN serum transfer arthritis (STA) models. METHOD: The flare variant of AIA was induced in wild-type mice and a blocking antibody to DKK1, control rat immunoglobulin G (IgG), or phosphate-buffered saline (PBS) was administered starting on day 14, a time at which inflammation and erosions are known to be established. Knees were assessed for histological inflammation and periosteal new bone formation was quantitated. In addition, STA was generated in transgenic (Tg) mice with osteoblast-specific overexpression of Dkk1 and littermate controls. New bone formation around the wrists of these mice was quantified by micro-computed tomography. RESULTS: Blockade of DKK1 in arthritic mice resulted in significantly more periosteal new bone formation compared to mice treated with control rat IgG or PBS. Conversely, in the setting of increased Dkk1 expression, arthritic Dkk1 Tg mice developed significantly less periosteal new bone than arthritic controls. CONCLUSION: DKK1 is a regulator of periosteal bone formation in inflammatory arthritis. Thus, regulation of DKK1 may be considered as a therapeutic approach in inflammatory diseases in which patients suffer from excessive periosteal bone formation, such as spondyloarthritis.
OBJECTIVE: The Wnt signalling antagonist Dickkopf-1 (DKK1) inhibits osteoblast differentiation and function and has been described to play a central role in promoting bone loss, while blockade of DKK1 increases bone formation. We investigated the effects of DKK1 on periosteal new bone formation in two murine models of inflammatory arthritis, the antigen-induced arthritis (AIA) and K/BxN serum transfer arthritis (STA) models. METHOD: The flare variant of AIA was induced in wild-type mice and a blocking antibody to DKK1, control rat immunoglobulin G (IgG), or phosphate-buffered saline (PBS) was administered starting on day 14, a time at which inflammation and erosions are known to be established. Knees were assessed for histological inflammation and periosteal new bone formation was quantitated. In addition, STA was generated in transgenic (Tg) mice with osteoblast-specific overexpression of Dkk1 and littermate controls. New bone formation around the wrists of these mice was quantified by micro-computed tomography. RESULTS: Blockade of DKK1 in arthritic mice resulted in significantly more periosteal new bone formation compared to mice treated with control rat IgG or PBS. Conversely, in the setting of increased Dkk1 expression, arthritic Dkk1 Tg mice developed significantly less periosteal new bone than arthritic controls. CONCLUSION: DKK1 is a regulator of periosteal bone formation in inflammatory arthritis. Thus, regulation of DKK1 may be considered as a therapeutic approach in inflammatory diseases in which patients suffer from excessive periosteal bone formation, such as spondyloarthritis.
Authors: A S Korganow; H Ji; S Mangialaio; V Duchatelle; R Pelanda; T Martin; C Degott; H Kikutani; K Rajewsky; J L Pasquali; C Benoist; D Mathis Journal: Immunity Date: 1999-04 Impact factor: 31.745
Authors: Frederic Morvan; Kim Boulukos; Philippe Clément-Lacroix; Sergio Roman Roman; Isabelle Suc-Royer; Béatrice Vayssière; Patrick Ammann; Patrick Martin; Sonia Pinho; Philippe Pognonec; Patrick Mollat; Christof Niehrs; Roland Baron; Georges Rawadi Journal: J Bone Miner Res Date: 2006-06 Impact factor: 6.741
Authors: Jun Guo; Minlin Liu; Dehong Yang; Mary L Bouxsein; Hiroaki Saito; R J Sells Galvin; Stuart A Kuhstoss; Clare C Thomas; Ernestina Schipani; Roland Baron; F Richard Bringhurst; Henry M Kronenberg Journal: Cell Metab Date: 2010-02-03 Impact factor: 27.287
Authors: Arne W Mould; Ian D Tonks; Marian M Cahill; Allison R Pettit; Ranjeny Thomas; Nicholas K Hayward; Graham F Kay Journal: Arthritis Rheum Date: 2003-09
Authors: S Uderhardt; D Diarra; J Katzenbeisser; J-P David; J Zwerina; W Richards; G Kronke; G Schett Journal: Ann Rheum Dis Date: 2009-03-19 Impact factor: 19.103